Get started
Author

Liangxing Zou

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study
2023 · Howard Sofen, Robert Bissonnette, et al. · EClinicalMedicine · 105
Pericardial late gadolinium enhancement and time to recurrence: a substudy from RHAPSODY, a phase 3 clinical trial of rilonacept in recurrent pericarditis
2023 · Paul C Cremer, David Lin, et al. · European Heart Journal - Imaging Methods and Practice · 27
PDF
Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY
2022 · Antonio Brucato, Michelle Z. Lim‐Watson, et al. · Journal of the American Heart Association · 27
PDF
Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis
2022 · Antonio Brucato, Alistair Wheeler, et al. · Heart · 19
PDF
Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.
2023 · William D. Tap, Andrew J. Wagner, et al. · Journal of Clinical Oncology · 8
Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
2024 · Michael C. Heinrich, Neeta Somaiah, et al. · Journal of Clinical Oncology · 4
PDF
Primary results of the phase 3 peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST).
2026 · Andrew J. Wagner, Jonathan C. Trent, et al. · Journal of Clinical Oncology · 3
Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
2025 · Jonathan C. Trent, Andrew J. Wagner, et al. · Journal of Clinical Oncology · 3
Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
2024 · Andrew J. Wagner, Jonathan C. Trent, et al. · Journal of Clinical Oncology · 3
PDF
Efficacy and Safety of Vixarelimab, a Human Monoclonal Oncostatin M Receptor Beta Antibody, in Moderate-to-Severe Prurigo Nodularis: A Randomised, Double-Blind, Placebo-Controlled Phase 2a Study
2022 · Howard Sofen, Robert Bissonnette, et al. · SSRN Electronic Journal · 3
Abstract 12057: Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and mRNA Vaccinations: Experience From Phase 3 Rhapsody Long-Term Extension
2022 · antonio brucato, Lucia Trotta, et al. · Circulation · 1
A first-in-human multi-center phase 1/2 study of a selective FGFR2/3 inhibitor, CGT4859, in patients with intrahepatic cholangiocarcinomas or other advanced solid tumors.
2025 · Lipika Goyal, Haley Ellis, et al. · Journal of Clinical Oncology
PDF
Works count: 12
Citation count: 202
H-index: 5
I10-index: 4
Year
Topic
Type